« Return to News | Drug Sponsors

Pfizer files NDA for new oncology drug

Wednesday, May 18, 2011 12:07 PM

Pfizer has filed a new drug application for its oncology drug crizotinib with regulators in the U.S. and Japan.

Crizotinib, an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor, has been accepted for filing and granted priority review status by the FDA. It has also been submitted to the Japanese Ministry of Health, Labour and Welfare for the treatment of patients with ALK-positive advanced non-small cell lung cancer (NSCLC).

Results from an expansion cohort of a phase I/II trial showed that at eight weeks, 87% of patients given crizotinib had responded to treatment—57% of those experiencing tumor shrinkage. About 3%-5% of NSCLC patients have tumors that are positive for the ALK- fusion gene.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.